Solid IO develops precision oncology tools to personalize cancer treatment plans. Their platform analyzes patient-specific data to identify optimal therapies and predict treatment response, ultimately improving outcomes for cancer patients.
Funding
$841.6K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
NSFounders
Product
Problem
Current cancer treatment strategies often rely on population-level data, leading to trial-and-error approaches that may not be effective for individual patients. The lack of patient-specific insights can result in unnecessary side effects, delayed access to optimal therapies, and increased costs for both patients and healthcare systems. Traditional drug development processes also face challenges in accurately predicting treatment responses and optimizing clinical trial designs.
Solution
Solid IO offers a patient-specific organ-on-chip platform that replicates the tumor microenvironment, providing real-time insights into how individual cancers respond to immuno-oncology treatments. By integrating bioengineering, microfluidics, and AI, the platform generates high-accuracy data on tumor-immune interactions, enabling clinicians to select the most effective therapies from day one. This approach reduces the need for trial-and-error, improves patient outcomes, and minimizes unnecessary side effects. Solid IO's technology also accelerates drug development by offering early patient stratification, biomarker validation, and treatment-response modeling, helping pharmaceutical companies optimize clinical trial designs and accelerate the development of new immuno-oncology drugs. The platform supports early-stage clinical trials for new drug development.
Target Audience
Solid IO's primary customers include pharmaceutical companies, biotech firms, cancer clinics, and research centers involved in immunotherapy and precision oncology research.
Features
- Patient-specific tumor microenvironment replication using organ-on-chip technology
- Real-time monitoring of tumor-immune interactions
- High-accuracy prediction of treatment responses to immunotherapies and combination treatments
- Integration of bioengineering, microfluidics, and AI for advanced analysis
- Biomarker validation and patient stratification capabilities
- Support for early-stage clinical trials and drug development
- 3D cell models combined with organ-on-chip principles
- Microfluidics and real-time functional readouts to replicate immune-tumor dynamics